Media coverage
19Media coverage
Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Canadian Life Sciences Database Country Switzerland Date 11/30/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Biotechgate Country Switzerland Date 11/30/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet BioSpace Country United States Date 11/30/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet PipelineReview Country Spain Date 11/30/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Canada NewsWire Country Canada Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet PR Newswire Country United States Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Canada NewsWire Country Canada Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet PR Newswire Country United States Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Canada NewsWire Country Canada Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet PR Newswire Country United States Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Nasdaq Country United States Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet India Pharma News Country India Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet TickerTech.com Country United States Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Stockwatch Country Canada Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet PharmiWeb Country United Kingdom Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Finanzen.ch Country Switzerland Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Markets Business Insider Country United States Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Spoke.com Country United States Date 11/29/18 Persons Jing Wang Title Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737 Media name/outlet Central Charts Country France Date 11/29/18 Persons Jing Wang